These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 21756009)

  • 1. Impact of persistence with infliximab on hospitalizations in ulcerative colitis.
    Carter CT; Leher H; Smith P; Smith DB; Waters HC
    Am J Manag Care; 2011 Jun; 17(6):385-92. PubMed ID: 21756009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of infliximab adherence on Crohn's disease-related healthcare utilization and inpatient costs.
    Carter CT; Waters HC; Smith DB
    Adv Ther; 2011 Aug; 28(8):671-83. PubMed ID: 21818671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of infliximab use in ulcerative colitis.
    Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
    Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infliximab as a rescue therapy for hospitalized patients with severe ulcerative colitis refractory to systemic corticosteroids.
    Yamamoto-Furusho JK; Uzcanga LF
    Dig Surg; 2008; 25(5):383-6. PubMed ID: 19005257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn's disease patients.
    Kane SV; Chao J; Mulani PM
    Adv Ther; 2009 Oct; 26(10):936-46. PubMed ID: 19838649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus.
    Yamamoto S; Nakase H; Matsuura M; Honzawa Y; Masuda S; Inui K; Chiba T
    J Gastroenterol Hepatol; 2010 May; 25(5):886-91. PubMed ID: 20546441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stability of infliximab dosing in inflammatory bowel disease: results from a multicenter US chart review.
    Waters H; Vanderpoel J; McKenzie S; Lunacsek O; Franklin M; Lennert B; Goff J; Augustyn DH
    J Med Econ; 2011; 14(4):397-402. PubMed ID: 21595522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resource utilization before and during infliximab therapy in patients with inflammatory bowel disease.
    Waters HC; Vanderpoel JE; Nejadnik B; McKenzie RS; Lunacsek OE; Lennert BJ; Goff J; Augustyn DH
    J Med Econ; 2012; 15(1):45-52. PubMed ID: 22023068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome following infliximab therapy in children with ulcerative colitis.
    Hyams JS; Lerer T; Griffiths A; Pfefferkorn M; Stephens M; Evans J; Otley A; Carvalho R; Mack D; Bousvaros A; Rosh J; Grossman A; Tomer G; Kay M; Crandall W; Oliva-Hemker M; Keljo D; LeLeiko N; Markowitz J;
    Am J Gastroenterol; 2010 Jun; 105(6):1430-6. PubMed ID: 20104217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Length of hospital stay and associated hospital costs with infliximab versus cyclosporine in severe ulcerative colitis.
    Löwenberg M; Duijvis NW; Ponsioen C; van den Brink GR; Fockens P; D'Haens GR
    Eur J Gastroenterol Hepatol; 2014 Nov; 26(11):1240-6. PubMed ID: 25171024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.
    Vande Casteele N; Ferrante M; Van Assche G; Ballet V; Compernolle G; Van Steen K; Simoens S; Rutgeerts P; Gils A; Vermeire S
    Gastroenterology; 2015 Jun; 148(7):1320-9.e3. PubMed ID: 25724455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization.
    Oussalah A; Evesque L; Laharie D; Roblin X; Boschetti G; Nancey S; Filippi J; Flourié B; Hebuterne X; Bigard MA; Peyrin-Biroulet L
    Am J Gastroenterol; 2010 Dec; 105(12):2617-25. PubMed ID: 20736936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ulcerative Colitis Treatment Patterns and Cost of Care.
    Null KD; Xu Y; Pasquale MK; Su C; Marren A; Harnett J; Mardekian J; Manuchehri A; Healey P
    Value Health; 2017 Jun; 20(6):752-761. PubMed ID: 28577692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients.
    Feagan BG; Reinisch W; Rutgeerts P; Sandborn WJ; Yan S; Eisenberg D; Bala M; Johanns J; Olson A; Hanauer SB
    Am J Gastroenterol; 2007 Apr; 102(4):794-802. PubMed ID: 17324131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infliximab in the treatment of steroid-dependent ulcerative colitis.
    Armuzzi A; De Pascalis B; Lupascu A; Fedeli P; Leo D; Mentella MC; Vincenti F; Melina D; Gasbarrini G; Pola P; Gasbarrini A
    Eur Rev Med Pharmacol Sci; 2004; 8(5):231-3. PubMed ID: 15638236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short- and long-term response to and weaning from infliximab therapy in pediatric ulcerative colitis.
    Fanjiang G; Russell GH; Katz AJ
    J Pediatr Gastroenterol Nutr; 2007 Mar; 44(3):312-7. PubMed ID: 17325550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.
    Pelletier EM; Ogale S; Yu E; Brunetta P; Garg J
    Clin Ther; 2009 Nov; 31(11):2653-64. PubMed ID: 20110008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis.
    Hyams J; Damaraju L; Blank M; Johanns J; Guzzo C; Winter HS; Kugathasan S; Cohen S; Markowitz J; Escher JC; Veereman-Wauters G; Crandall W; Baldassano R; Griffiths A;
    Clin Gastroenterol Hepatol; 2012 Apr; 10(4):391-9.e1. PubMed ID: 22155755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infliximab for refractory ulcerative colitis.
    Chey WY; Hussain A; Ryan C; Potter GD; Shah A
    Am J Gastroenterol; 2001 Aug; 96(8):2373-81. PubMed ID: 11513177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis.
    Tsai HH; Punekar YS; Morris J; Fortun P
    Aliment Pharmacol Ther; 2008 Nov; 28(10):1230-9. PubMed ID: 18729845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.